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Biweekly rituximab, cyclophosphamide, vincristine,
non-pegylated liposome-encapsulated doxorubicin and
prednisone (R-COMP-14) in elderly patients with poor-risk
diffuse large B-cell lymphoma and moderate to high ‘life threat’
impact cardiopathy
Elderly patients with newly diagnosed diffuse large B-cell
lymphoma (DLBCL) and a poor prognostic proﬁle, according
to the International Prognostic Index (IPI), were shown to
beneﬁt from shortening of the time interval between CHOP
(cyclophosphamide, doxorubicin, vincristine and prednisone)
chemotherapy cycles from 3 weeks (CHOP-21) to 2 weeks
(CHOP-14) (Pfreundschuh et al, 2004, 2008). In these
patients, biweekly CHOP plus rituximab (R) (R-CHOP-14)
is regarded as a therapeutic standard for some cooperative
groups and is a valuable option in clinical practice (Pfreund-
schuh et al, 2008; Rueda et al, 2008; Ziepert et al, 2010; Zwick
et al, 2007).
Further exploration of dose-densiﬁed approaches to treat
high-risk DLBCL in the elderly appears also justiﬁed due to: (i)
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Summary
This Phase II study assessed feasibility and efﬁcacy of a biweekly R-COMP-14
regimen (rituximab, cyclophosphamide, non-pegylated liposome-encapsulated
doxorubicin, vincristine and prednisone) in untreated elderly patients with
poor-risk diffuse large B-cell lymphoma (DLBCL) and moderate to high ‘life
threat’ impact NIA/NCI cardiac comorbidity. A total of 208 courses were
delivered, with close cardiac monitoring, to 41 patients (median age:
73 years, range: 62–82; 37% >75 years) at a median interval of 15Æ6 (range,
13–29) days; 67% completed all six scheduled courses. Response rate was
73%, with 68% complete responses (CR); 4-year disease-free survival (DFS)
and time to treatment failure (TTF) were 72% and 49%, respectively. Failures
were due to early death (n = 3), therapy discontinuations (no-response
n = 2; toxicity n = 6), relapse (n = 6) and death in CR (n = 3). Incidence of
cardiac grade 3–5 adverse events was 7/41 (17%; 95% conﬁdence interval:
8–31%). Time to progression and overall survival at 4-years were 77% and
67%, respectively. The Age-adjusted Charlson Comorbidity Index (aaCCI)
correlated with failures (P =0 Æ007) with patients scoring £7 having a longer
TTF (66% vs. 29%; P =0 Æ009). R-COMP-14 is feasible and ensures a
substantial DFS to poor-risk DLBCL patients who would have been denied
anthracycline-based treatment due to cardiac morbidity. The aaCCI
predicted both treatment discontinuation rate and TTF.
Keywords: non-pegylated liposomal doxorubicin, elderly, diffuse large B-cell
lymphoma, cardiotoxicity, Charlson Comorbidity Index.
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with poor IPI risk given R-CHOP-21 (Feugier et al, 2005) and
their low chance of achieving a durable second remission
(Corazzelli et al, 2009; Gisselbrecht et al, 2009), (ii) the
comparable toxicity of R-CHOP-21 and R-CHOP-14 in terms
of cardiac complications (Cunningham et al, 2009; Delarue
et al, 2009; Pfreundschuh et al, 2004), (iii) the prospect of a less
protracted, if not halved, therapy duration in elderly patients
who display a limited physical and psychosocial compliance to
prolonged treatments, and (iv) the recent recognition of the
highly aggressive entity ‘Epstein-Barr virus (EBV)-positive
DLBCL of the elderly’ (12% to 33% of DLBCL) with a median
progression free survival of only about 1 year upon CHOP-21
+/) Rituximab (Park et al, 2007; Swerdlow et al, 2008).
Delivery of densiﬁed R-CHOP in older patients with heart-
related morbidities, may however, be challenging because
of the acute, early and late cardiotoxicities of doxorubicin
(Grann et al, 2006; Hershman et al, 2008). Prolongation of the
QTc interval, arrhythmias, myopericarditis and increase of
N-terminal (NT)-pro brain natriuretic peptide (proBNP), an
early biomarker of ventricular dysfunction, were described
during CHOP-like programmes, independently of the cumu-
lative doxorubicin dosing (Elliott, 2006; Johnson, 2006). In
general, the suggestion that ﬁt patients with DLBCL, even if
aged more than 80 years, should be evaluated for ‘adapted’
anthracycline-based regimens with curative intent (Bairey et al,
2006; Peyrade et al, 2010; Thieblemont et al, 2008) has to face
the problem of cardiac risk factors and comorbidities. In this
regard, the therapeutic approach remains pragmatic also due to
the absence of international guidelines on cardioprotective
agents and of uniform strategies for patients with cardiac risk
factors (Hensley et al, 2009). A consensus regarding the optimal
methods for cardiac monitoring during anthracycline chemo-
therapy is also lacking (Altena et al, 2009), so that current
guiding principles areabout the sameas those used 20 years ago
(Cheitlin et al, 2003; Klocke et al, 2003; Schwartz et al, 1987).
Such issues are very relevant in the context of population-based
practice, i.e. involving ‘non-study’ patients, where, differently
from controlled trials, selection criteria and therapy optimiza-
tion do not usually apply (Thieblemont & Coifﬁer, 2007).
The application of liposome-encapsulated formulations of
doxorubicin has been suggested as a strategy to minimize
cardiac side effects and favour a more selective drug uptake by
lymphoma cells (Allen & Martin, 2004). Liposomal formula-
tions display comparable efﬁcacy with free anthracyclines, but
are linked to more favourable bioavailability and biodistribu-
tion proﬁles (Batist et al, 2001; Levine et al, 2004; Tsavaris
et al, 2002; Zaja et al, 2006). This enables the delivery of higher
cumulative doses of liposomal anthracyclines with a lower risk
of heart failure as compared to the parent compounds (Young
et al, 2004). Whether the use of these liposome-encapsulated
formulations might also represent a tool for the application of
curative dose-intense regimens to older patients with highly
chemosensitive tumours in the presence of cardiac risk factors,
remains to be assessed.
To this end, we have conducted a pilot study to explore a
dose-dense R-CHOP-like regimen (R-COMP-14) including
non-pegylated liposome-encapsulated doxorubicin (NPLD) in
elderly DLBCL patients falling into a poor-prognostic group by
standard IPI and presenting moderate to high ‘life threat’
impact cardiopathy, as deﬁned by the National Institute on
Aging and the National Cancer Institute (NIA/NCI) criteria
applied to non-Hodgkin lymphoma (NHL) (Janssen-Heijnen
et al, 2005; Yancik et al, 1998). Patients were concurrently
assessed through the age-adjusted Charlson Comorbidity
Index (aaCCI) (Charlson et al, 1987; Hall et al, 2004; Thie-
blemont & Coifﬁer, 2007). We evaluated the feasibility of this
biweekly R-COMP regimen, as indicated by the actual
proportion of patients fully receiving the planned treatment,
the incidence of cardiac adverse events (AE), and its
therapeutic efﬁcacy in terms of response and survival out-
comes.
Patients and methods
Patients selection
This unsponsored study was approved by local ethic commit-
tees and conducted according to the Good Clinical Practice
guidelines and the Declaration of Helsinki. All patients gave
written informed consent to treatment and use of clinical data
for research. Eligible patients were required to have newly
diagnosed histologically conﬁrmed DLBCL according to the
World Health Organization (WHO) Lymphoma Classiﬁcation
(Jaffe et al, 2001), age > 60 years, intermediate-high and high
standard IPI risk (The International Non-Hodgkin’s Lym-
phoma Prognostic Factors Project., 1993) and one or more
condition(s) of moderate to high ‘life threat’ impact cardiac
morbidity. This latter was deﬁned according to the NIA/NCI
index (Yancik et al, 1998) as applied to non-Hodgkin
lymphoma patients (Janssen-Heijnen et al, 2005). In this
regimen, an equal dose of NLPD was substituted for doxoru-
bicin within the R-CHOP-14 platform. The following eligibil-
ity criteria were also required: negativity for human
immunodeﬁciency virus and surface antigen of hepatitis B,
Eastern Cooperative Group performance status (ECOG PS)
0–3, no previous chemotherapy or radiotherapy, creatinine
clearance (CrCl) >30 ml/min, serum transaminases less than
three times the normal value, bilirubin <34Æ2 lmol/l, absolute
neutrophil count ‡1000 · 10
9/l, haemoglobin level ‡100 g/l,
and platelet count ‡75 000 · 10
9/l, no history of congestive
heart failure (CHF), left ventricular ejection fraction (LVEF)
‡45% at bi-dimensional echocardiography or, in selected cases
(i.e. obese patient), multiple uptake gated acquisition (MUGA)
scintigraphy. Myocardial infarction represented an exclusion
criteria only if diagnosed within 12 months prior to R-COMP-14.
Comorbidity was assessed with the aaCCI (Charlson et al,
1987; Hall et al, 2004). Pre-treatment disease assessment
included a contrast-enhanced total-body computed tomog-
raphy scan, Fluorine-18 (18F)-Fluorodeoxyglucose Positron
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and lumbar puncture in case of testicular, breast, epidural or
sinus involvement. Restaging was scheduled after three courses
and a ﬁnal evaluation was performed 4 weeks after the end of
chemotherapy. No consolidation radiotherapy was scheduled.
Treatment
Patients were scheduled to receive six courses of R-COMP-14
(rituximab 375 mg/m
2 on day 1, cyclophosphamide 750 mg/
m
2 on day 2, NLPD-Myocet
  50 mg/m
2 on day 2, vincristine
1Æ4 mg/m
2, up to a maximal dose of 2 mg on day 2, and
prednisone 40 mg/m
2 per day for 5 d) at a 2-week interval.
Myocet
  was purchased from Cephalon, Rome, Italy. Primary
granulocyte colony-stimulating factor (G-CSF) support was
employed from day 6 to day 10 of each course. The agent-
speciﬁc relative dose intensity (RDI) for each drug was
calculated as the ratio between the administered dose and
the planned dose, described in mg/m
2 per week. The regimen
was administered on an inpatient basis for the ﬁrst four
courses and a 3–5 d prednisone pretreatment was given before
the ﬁrst cycle to patients with ECOG PS >1. All patients
received rasburicase and appropriate hydration/alkalinization
during the ﬁrst course. Intrathecal prophylaxis with 50 mg of
liposome-encapsulated cytarabine (Depocyte
 ; Mundiphar-
ma, Cambridge, UK), on day 2 of cycles 1–4, was given in cases
at risk for central nervous system (CNS) localization. No
continuous use of acyclovir and cothrimoxazole was recom-
mended but patients received ciproﬂoxacin and/or azythro-
mycin prophylaxis, while ﬂuconazole was employed as needed;
febrile neutropenia was managed by hospitalization.
The prescription of QTc interval-prolonging drugs, such as
some ﬂuoroquinolones, macrolide antibiotics and itraconaz-
ole, was discouraged (Liu & Juurlink, 2004; Wolbrette, 2004),
as well as use of tricyclic antidepressants, haloperidol and
selective serotonin reuptake inhibitors (Liu & Juurlink, 2004;
Wolbrette, 2004). Electrocardiography was repeated before
each course together with bi-dimensional echocardiographic
survey. No protocol-committed pre-emptive strategy was
planned with agents recognized to have protective activity
from doxorubicin-related cardiotoxicity, such as beta-blockers,
angiotensin-converting-enzyme inhibitors (ACEI) and angio-
tensin receptor blockers (ARB); however patients continued to
take their daily background cardiological medications, includ-
ing beta-blockers and ACEI/ARB if previously prescribed.
Toxicity and dose modulation
Toxicity was evaluated using the NCI Common Terminology
Criteria for Adverse Events (CTCAE) v3.0 toxicity scale (http://
ctep.cancer.gov/protocolDevelopment/electronic_applications/
docs/ctcaev3.pdf). Full blood cell counts, together with renal
and hepatic function tests, were planned twice weekly after the
ﬁrst R-COMP-14 and weekly thereafter. The next chemother-
apy cycle was scheduled at day 15, if neutrophil count
>1000 · 10
9/l and platelet count >75 000 · 10
9/l. If the
platelet count was <75 000 · 10
9/l the course was delayed
for up to 2 weeks. In case of grade 4 thrombocytopenia, the
doses of cyclophosphamide and doxorubicin were decreased
by 25%. Dose reduction guidelines also included: (i) vincris-
tine reduction, to a ﬁxed dose of 1 mg, in case of grade 2
peripheral neuropathy or serum bilirubin 25Æ65–51Æ3 lmol/l or
transaminases 2–3 times upper limit of normal (ULN) or
alkaline phosphatase increased; decrease to 25% of dose if
serum bilirubin 51Æ3–85Æ5 lmol/l; avoid use for grade 3–4
peripheral neuropathy, or serum bilirubin >85Æ5 lmol/l or
aspartate transaminase >180 units, (ii) decrease cyclophos-
phamide to 75% of dose in case of CrCl <10 ml/min; and
serum bilirubin 53–85Æ5 lmol/l or transaminases >3 times
ULN; avoid use if serum bilirubin >85Æ5 lmol/l, and (iii)
decrease of NPLD to 50% for bilirubin 34Æ2–51Æ3 lmol/l; to
25% for bilirubin 51Æ3–85Æ5 lmol/l. The doses of rituximab
were not modiﬁed. Treatment was stopped in case of no
response, lymphoma progression, patient refusal or, at the
treating physicians judgment, in cases of intercurrent illness.
Therapy was also withdrawn in case of the following CTCAE
v3.0 grade 3 and 4 cardiac adverse events: (i) conduction
abnormality/arrhythmia incompletely controlled medically
(grade 3) or associated with CHF, hypotension, syncope or
shock (grade 4), (ii) symptoms and testing consistent with
ischaemia, unstable angina (grade 3) or acute myocardial
infarction (grade 4), (iii) cardiac troponin serum levels
consistent with unstable angina (grade 3) or myocardial
infarction (grade 4), (iv) symptomatic left ventricular systolic
dysfunction with CHF, or resting ejection fraction <40%
responsive to intervention (grade 3) or poorly controlled
(grade 4), (v) pericardial effusion with physiological (grade 3)
or life-threatening consequences (grade 4), and (vi) symp-
tomatic valvular disease controlled with medical therapy
(grade 3), or life-threatening/disabling (grade 4).
Endpoints
The primary safety endpoint was the incidence of cardiac
events, deﬁned as deﬁnite cardiac death, sudden death without
documented non-cardiac aetiology and the occurrence of
grade 3 and 4 cardiac adverse events according to CTCAE v3.0.
The primary efﬁcacy endpoints were complete response (CR)
rate and time to treatment failure (TTF). Criteria for remission
and survival outcomes were as published (Cheson et al, 2007).
TTF was computed from the ﬁrst day of treatment to either
disease progression, relapse, or R-COMP-14 discontinuation
due to patient refusal, grade 3 and 4 cardiac AE or the treating
physicians decision on intercurrent illness. Death without
progression within 4 weeks after the start of therapy was
designated as early therapy-related death. Death without
progression after completion of the whole treatment was also
considered therapy-related if due to cardiac events. The age
cut-off of 70 years and aaCCI were analysed for correlation
with TTF.
R-COMP-14 for Poor-risk DLBCL in the Cardiopathic Elderly
ª 2011 Blackwell Publishing Ltd, British Journal of Haematology, 154, 579–589 581Secondary endpoints were time to progression (TTP),
overall survival (OS) and disease-free survival (DFS) in
complete responders. TTP was measured from the ﬁrst day
of treatment to the date of documented lymphoma progression
or death as a result of lymphoma. OS was measured from the
ﬁrst day of treatment to the date of death as a result of any
cause or last follow-up. DFS was calculated from the time of
occurrence of CR until relapse or death as a result of
lymphoma or treatment toxicity.
Statistics
In order to avoid unacceptable toxicity, the Bryant and Day
two-stage phase II trial design was chosen with aR = aT =0 Æ1
and b =0 Æ2. A cut-off point for the response rate (70%) and
for severe cardiac events (20%) was established for the ﬁrst 19
patients. On this basis, the completed stage-one trial of 19
patients proceeded to stage-two, up to 40 patients, if there
were at least 11 responses and 13 ‘safe’ patients (Bryant & Day,
1995). Probabilities of early termination of the study in case of
excessive toxicity were 72% in the presence of good response
and 90% in case of poor response. Survival endpoints were
analysed using the approach of Kaplan and Meier and
estimations at 4 years were calculated with 95% conﬁdence
intervals (CI). Univariate analyses were performed using
Fisher’s exact test and log rank test. Non-parametric linear
regression was performed for correlation analysis. All P values
were two-tailed. All efﬁcacy and toxicity endpoints were
updated at December 2010. Statistical analysis was performed
with the Statistical Package for the Social Sciences (spss),
version 14.0 (SPSS, Chicago, IL, USA).
Results
A total of 41 patients were prospectively accrued between
January 2007 and July 2009; the two stages of the study design
were both completed in the absence of excessive toxicity or
unacceptably poor outcome and all patients were evaluable for
toxicity and response. In stage-one of the study 19 patients
were enrolled: the overall response rate (ORR) was 73Æ7% [13
CRs and one partial response (PR)], with severe cardiac events
occurring in 11% of patients. Given that a response rate of at
least 70% and a £20% incidence of severe cardiac events were
required to proceed to stage-two, an additional 22 patients
were enrolled. No statistically signiﬁcant differences were
detected between patients accrued in the two stages in terms of
demographics, disease characteristics, comorbidity at presen-
tation, and response to treatment (Table S1).
Base-line characteristics
The clinical features of the entire patient population are
summarized in Table I. The median age at the time of
inclusion was 73 years and 15 patients (37%) were older than
75 years. Twenty-four patients had an IPI of 3, and in 17 the
IPI was ‡4; 27 patients (71%) were in stage IV, 49% had B
symptoms and 32% were assigned an ECOG PS > 1.
The distribution of heart-related conditions with ‘life threat’
impact is also detailed in Table I. Moderate impact conditions,
such as prior myocardial infarction and valve disease were
present in 11 and seven cases respectively, while a large
Table I. Patient characteristics.
Characteristics n %
Patients entered 41 100
Age at treatment (years)
Median (range) 73 (62–82)
61–65 6 15
66–70 9 22
71–75 11 27
76–80 10 24
>80 5 12
Male gender 23 56
Clinical stage
II 4
III 10 24
IV 27 66
B symptoms 20 49
No of extranodal sites ‡ 21 4 3 4
Bone marrow involvement 9 22
Lactate dehydrogenase > ULN 33 81
ECOG performance Status ‡ 21 3 3 2
Standard IPI score
32 4 5 9
4–5 17 41
Basal LVEF value (%)
Median 57
Range 45–67
Cardiovascular risk factors
Chronic renal failure (GFR
30–50 ml/min per 1Æ73 m
2)
51 2
Hypertension, UAT 12
Diabetes mellitus, UAT 8
Hyperlipidemia, UAT 14
Moderate impact heart-related conditions 18 44
Prior myocardial infarction (>1 year) 11 27
Valve disease 7 17
High impact heart-related conditions 23 56
Chronic, multivessel coronary disease, UAT 19 46
Atrial ﬁbrillation, UAT 9 22
Conduction disturbances, UAT 10 24
Hypertensive heart disease, UAT 4 10
Beta-blockers and/or ACEI/ARB
background treatment
27 65
Age-adjusted Charlson Comorbidity Index
Median 8
Range 5–12
ULN, upper limit of normal range; ECOG, Eastern Cooperative
Oncology Group; GFR, glomerular ﬁltration rate; UAT, under active
treatment; LVEF, left ventricular ejection fraction; IPI, international
prognostic index; ACEI, angiotensin-converting-enzyme inhibitors;
ARB, angiotensin receptor blockers.
G. Corazzelli et al
582 ª 2011 Blackwell Publishing Ltd, British Journal of Haematology, 154, 579–589proportion of patients (56%) presented high-impact situations
mainly consisting of ischaemic and arrhythmic cardiac diseases
under active treatment (Table I). Cardiac risk factor hyper-
tension, diabetes mellitus and dyslipidaemia were under
medication in 34 cases, while moderate chronic renal failure
(glomerular ﬁltration rate 30–50 ml/min) affected 12% of
patients. Two-thirds of patients had background treatment
including ACEI/ARB and/or beta blockers. Median basal
echocardiographic LVEF for the entire study population was
57% (range,45–67). Median aaCCI was 8 (range, 5–12).
Primary endpoints
The scheduled six courses of R-COMP-14 were completed by
27 patients (67%), including two patients who received two
additional courses as CR consolidation for a destructive bone
involvement (Table II). In these latter patients, aged 72 and
81 years, radiotherapy was excluded to allow osteosynthesis
(right omerus, epiphyseal-metaphyseal area) in one case, and
avoid post-actinic damage (left maxillary sinus, pterigoides
laminae, left greater sphenoid wing and ethmoid septum) in
the other. Three patients, aged 82, 69 and 78 years, all in CR at
intermediate restaging, were considered to have completed
their treatment after ﬁve courses (Table II): the ﬁrst patient
did not attend the scheduled sixth course for logistic reasons
after relatives referred her to a distant community dwelling; the
second skipped his sixth course so as not to delay radiofre-
quency ablation treatment of hepatocellular carcinoma; in the
third patient, a psychiatric counsellor, upon the occurrence of
a severe isolated memory loss of unknown cause, advised
skipping the last course. These three complete responders were
not considered as failures due to toxicity, treatment discon-
tinuation or refusal.
Overall, a total of 208 courses were delivered, with a median
time to recycle of 15Æ6 d (range, 13–29). Treatment delivery
achieved an average RDI of 88Æ6% (cyclophosphamide 86%,
NPLD 89%, vincristine 91%). Three patients received CNS
prophylaxis with intrathecal liposomal cytarabine due to
epidural (n = 2) and paranasal sinus (n = 1) localizations.
Discontinuation for toxicity occurred in a total of six
patients (15%). This was due to widespread herpes zoster
infection (n = 1) and grade 3 cardiac events (n = 5), namely
decrease in LVEF (n = 3) and grade 3 and grade 4 arrhythmia
(n = 2) (Table II). After stopping R-COMP-14, all these six
patients did not receive any further chemotherapy but were
given additional doses of rituximab, at biweekly intervals, up
to a total of eight (n = 4) or ibritumomab-tiuxetan (n = 2).
The cumulative incidence of failures due to early and late
cardiac events was 17% (7/41; 95% CI 8% to 31%).
The ORR was 73% with 28 patients achieving CR (68%;
95% CI 54% to 82%). After a median period of observation for
TTF of 27 months, 20 failures according to the protocol were
observed: three early therapy-related deaths [at day +12
(undeﬁned cause) and +13 (sepsis) of the ﬁrst course, and at
day +18 (sepsis) from the second cycle, respectively], eight
treatment discontinuations [no response, i.e. less than PR/
progressive disease (n = 2), toxicity (n = 6)], six relapses,
three lymphoma-unrelated deaths in continuous CR, due to
decompensated cirrhosis (n = 1) and late cardiac events
(n = 2).
The 4-year TTF was 49% (95% CI 33% to 65%, median
19Æ2 months) without a signiﬁcant advantage for patients
younger than 70 years (63% vs. 40%; P =0 Æ12) (Table III,
Figs 1A and 2A). In contrast, a statistically signiﬁcant corre-
lation with treatment failure was found for the aaCCI
(r
2 =0 Æ17, P =0 Æ007) (Fig 3). In particular, patients with an
aaCCI score £7 (66%; 95% CI 46–86) displayed a longer TTF
as compared to those with a score >7 (29%; 95% CI 8% to
49%)(P =0 Æ009) (Fig 2B). Early deaths and toxicity-related
therapy discontinuations were also signiﬁcantly more frequent
among patients with aaCCI scores >7 (P =0 Æ02), while these
events were not predicted by chronological age (Table III).
Median values of LVEF for the entire study population
documented at 1 year after completion of treatment were
superimposable to those present before treatment (Fig 4A),
but differences in quartiles were evident. At midtreatment
evaluation the LVEF had a 5% to 10% decrease in eight
patients, while a >10% reduction was observed in ﬁve others.
Table II. Feasibility of R-COMP-14: status of patients and cause of termination of therapy after each cycle.
No. of patients (%)
Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6 Cycle 7 Cycle 8 Total
Patients receiving therapy 41(100) 39 (95) 36 (88) 31 (80) 30 (73) 27(67) 2 2
Early death 2 1 3 (7)
Discontinuation for toxicity 2 3 1 6 (15)
LVEF <40% 2 1 3 (7)
CTCAE Grade 3 arrhythmia 1 2 (5)
CTCAE Grade 4 arrhythmia 1
Disseminated Zoster 1 1
Diversion for no response 2 2
Treatment completed 3 25 2 30 (73)
LVEF, left ventricular ejection fraction; CTCAE, Common Terminology Criteria for Adverse Events version 3.0.
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stopped per protocol becuase the CTCAE limit for grade 3
toxicity, i.e. a LVEF <40%, was reached. Nevertheless, the
remission status achieved by these three patients allowed a
time to progression of 12+, 15+ and 16+ months, which was
paralleled by a progressive recovery of their LVEF values. At
1 year from completion of treatment, 23 of 29 surviving
patients did not show signiﬁcant differences in LVEF as
compared to pre-therapy values. A 10% to 15% reduction of
LVEF was recorded in six cases, while two patients displayed a
LVEF value below 40% (Table II and Fig 4B).
Haematological toxicity was acceptable, with grade 3 and 4
thrombocytopenia occurring in nine patients (22%), grade 3
and 4 anaemia in six (15%) and grade 3 and 4 infections in
eight (19%). Notably, at the time of ﬁnal restaging, focal lung
parenchymal uptake at FDG-PET was found in six patients
(ﬁve of them were aged >75 years), which qualiﬁed as
pulmonary infection (no Pneumocystis spp) and was treated
effectively with antibacterial agents.
Secondary endpoints
Among 28 complete responders, eight events were recorded,
namely ﬁve relapses and three deaths in CR at months 13, 14
and 16, respectively; the ﬁrst death was due to hepatic
cirrhosis, the second to a sudden death, considered per
protocol as a ‘cardiac event’ in the absence of any documented
aetiology, the third to CHF. According to the adopted
standardized criteria for DFS endpoint (Cheson et al, 2007),
the ﬁrst patient was censored at month 13, while the second
and the third cases were both included as events, with a 4-year
DFS of 72% (95% CI 55% to 90%) (Fig 1B).
Overall, 12 patients (29%) died (Table III), yielding to an
estimated 4-year OS of 67% (95% CI 52% to 83%). Causes of
death included early toxic event (n = 3), lymphoma progres-
sion (n = 6) and lymphoma-unrelated cause (n = 3). The TTP
rate was 77% (95% CI 69% to 91%) (Table III and Fig 1A).
TTP survival analysis also included the six patients who had
discontinued treatment due to toxicity. Among them, there
were four CRs with a TTP of 12, 16, 20+ and 29+ months
respectively, and two initial PRs whose TTP ended at months 8
and 14.
Discussion
This prospective study addressed two issues relevant to the
management of DLBCL in the elderly. The ﬁrst was to assess
whether substitution of NPLD for conventional doxorubicin
allowed the safe application of a dose-densiﬁed R-CHOP-like
regimen to older patients with poor-risk disease (IPI ‡ 3) and
moderate to high ‘life threat’ impact (NIA/NCI) cardiac
comorbidity. The second was to evaluate the potential clinical
beneﬁt of R-COMP-14 in terms of CR, TTF and DFS rates in
this subset of high-risk patients.
About two-thirds of patients completed the entire six-course
programme with a median average RDI approaching 90% for
all of the drugs. These proportions are valuable because about
one-third of patients were older than 75 years, i.e. above the
Table III. Response to therapy and events according to age and aaCCI.
Total
Age £ 70
years Age > 70 years aaCCI £ 7 aaCCI > 7
(n = 41) (n = 15) (n = 26) (n = 19<) (n = 22)
n % 95% CI n % n % P* n % n% P *
Overall response rate 30 73 60–87 13 87 17 65 0Æ16 17 89 13 59 0Æ47
CR 28 68 54–82 12 80 16 61 0Æ30 15 79 13 59 0Æ62
PR 2 1 1 2
Less than PR 2 1 1 1 1
Discontinuation 6 15 4–25 0 6 23 0Æ11 15 2 3 0Æ02
Early therapy-related deaths 3 7 1–15 1 2 3
Relapsed 6 21 6–37
Deaths for lymphoma 6 15 4–25 2 4 4 2
Deaths unrelated 1 1 1
Late therapy-related deaths 2 1 1 1 1
Alive 29 70 57–85 11 73 18 69 14 73 15 68
4-year survival
TTF 49 33–65 63 40 0Æ12 66 29 0Æ009
TTP 77 64–91 84 67 0Æ32 77 70 0Æ88
OS 67 52–83 70 64 0Æ75 71 65 0Æ49
DFS 72 55–90 80 66 0Æ40 77 67 0Æ63
aaCCI, age-adjusted Charlson comorbidity index; CR, complete response; PR, partial response; TTF, time to treatment failure; TTP, time to
progression; OS, overall survival; DFS, disease-free survival.
*All P values are two-sided.
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et al, 2005; Pfreundschuh et al, 2004). Response rate was
aligned with results of non-cardiopathic patients with unfa-
vourable IPI proﬁles (Pfreundschuh et al, 2008). The substantial
DFS achieved supports the use of dose-dense treatment is worth
ensuing also when age and cardiac comorbidity increase the
complexity of lymphoma management and may affect survival
(Aapro et al, 2010). The TTF, though hardened by a strict
deﬁnition of failures, was also in keeping with recent literature
(Feugier et al, 2005; Pfreundschuh et al, 2008). Early treatment
discontinuation for toxicity occurred in only 15% of patients,
all older than 70 years. All of these patients, despite receiving a
reduced number of R-COMP-14 courses (median 3, range
2–4), achieved objective responses and contributed to the TTP
curve. This indicates that delivery of even fewer cycles of
doxorubicin-based chemotherapy remains an option to pursue
in non-frail patients older than 70 years (Chrischilles et al,
2003). In this regard, application of fewer courses of densiﬁed
R-COMP-14 might be of value.
Although the importance of dose-intensity in aggressive
NHL was conﬁrmed in the rituximab era (Hirakawa et al,
2010), the superiority of R-CHOP-14 over R-CHOP-21 is
highly debated, also due to interim results of ongoing
randomized trials (Cunningham et al, 2009; Delarue et al,
2009). While these studies will eventually clarify the issue,
R-CHOP-14 remains a possible option for elderly patients with
a high IPI risk, given the signiﬁcant relapse rate of R-CHOP-21
in this speciﬁc patient population (Feugier et al, 2005) and the
inadequate results of salvage treatments (Corazzelli et al, 2009;
Gisselbrecht et al, 2009). Concerns about the toxicity of
biweekly R-CHOP, especially with regard to cardiac morbidity
and infectious risk (Johnson, 2006; Tadmor et al, 2010), may
restrain physicians from proposing this strategy to elderly
individuals. Irrespective of dose-densiﬁcation, older DLBCL
patients with comorbidity, underlying heart disease, and/or
poor PS are often precluded ‘a priori’ from a curative
treatment. These conditions should not ‘per se’ contraindicate
the application of R-CHOP (Johnson, 2006). This may reﬂect a
cultural reluctance to treat individuals with a presumed
defective resilience to treatment toxicity and the inadequacy
of instruments to properly identify subclinical damage and
prompt timely preventive measures and/or treatment inter-
ruptions (Aapro et al, 2010; Thieblemont & Coifﬁer, 2007).
The present study was designed to overcome this conceptual
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Fig 1. Kaplan–Meier survival curves for the whole cohort (n = 41) (A)
and complete responders (n = 28) (B).
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Fig 2. Time to treatment failure according to age cut-off 70 years (A)
and aaCCI (B).
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taining regimen for patients with cardiac comorbidity through
strict patient monitoring.
The cumulative incidence of failures due to grade 3–5
cardiac events was only 17% in our study. This proportion is
apparently higher than that reported (5%) in a study of 72
elderly DLBCL patients treated with a 3-weekly R-COMP
regimen (Luminari et al, 2010). However, strict enrollment
criteria limited the overall burden of comorbidity in this latter
study, as witnessed by the presence of clinically signiﬁcant
arrhythmic or ischaemic disease in only 14% of patients and
the absence of cardiovascular risk factors in 47% of the cases
(Luminari et al, 2010). A 5% to 15% incidence of grade 3–5
cardiovascular events was reported in two small series of
elderly patients treated with an R-COMP-21 regimen (Rigacci
et al, 2007; Visani et al, 2008). However, concomitant accrual
of naı ¨ve and pretreated or frail patients, coupled to the
heterogeneity and variable severity of cardiac comorbidity and
cardiovascular risk factors in these two series, hampers a
comparison with our study.
In ﬁve of our patients with normal pretreatment LVEF
values, grade 3 cardiac events with LVEF reduction occurred
between the 2nd and 4th course of R-COMP-14, despite the
low cumulative dose of NPLD. Previous CHOP studies have
described LVEF declines at a cumulative doxorubicin dose of
only 200 mg/m
2 (Limat et al, 2003; Nousiainen et al, 2002),
highlighting diastolic dysfunction and heart failure with
preserved left ventricular systolic function as early predictors
of cardiotoxicity (Pudil et al, 2008). This suggests that LVEF
should not be the only tool for the assessment of early
cardiotoxicity in older NHL patients with preexisting cardi-
opathy but that additional cardiological evaluations and
biomarkers studies are necessary (Albini et al, 2010; Altena
et al, 2009). Serial measurements of proBNP levels were
available in 44% of our patients (data not shown), but the
presence of pre-treatment proBNP levels above the age-
adjusted cut-off values, and their variations due to cardiolog-
ical therapy, anaemia, infections and renal disease, affected the
speciﬁcity and predictive value of this biomarker, as previously
reported (Dodos et al, 2008).
The aaCCI, a prototypical and reliable comorbidity index,
which includes lymphoma among the weighted medical
conditions, was a robust predictor of treatment outcomes
and survival in our cohort of cardiopathic DLBCL patients.
Intriguingly, aaCCI scoring was a better predictor for early
death and toxicity-related therapy discontinuation than age
itself. This data supports the application of indexes, such as the
aaCCI, in the speciﬁc situation of elderly NHL patients with
heart disease. In this context, comorbidity assessment may
account for breakthrough non-cardiac morbidities, including
chronic renal failure, lung diseases, endocrine disorders (Khan
et al, 1999), neutropenic sepsis (Ammann et al, 2001; ver Elst
et al, 2000) or hypovolemic/hypotensive problems (Arlati et al,
2000), which can trigger secondary cardiac dysfunctions
unrelated to cardiotoxicity from chemotherapy.
Patients in our study could have beneﬁted from a protective
effect and/or improved cardiac compensatory mechanisms
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Fig 3. Correlation of aaCCI with treatment failure. Regression line
with 95% conﬁdence band.
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ventricular systolic dysfunction’ occur.
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whether preexisting heart disease increases susceptibility to
anthracycline-induced damage or the impaired cardiac func-
tional reserve increases vulnerability of older patients to
additional myocardial injures (Hershman et al, 2008), a
beneﬁcial pharmacological action from beta-blockers and/or
ACEI or ARB assumed by about two-thirds of our patients
may be supposed. Notably, while a large amount of data on
cardioprotective strategies was generated in childhood cancers
and solid tumours (Cardinale et al, 2006; Lipshultz & Colan,
2004), information is scanty for DLBCL, a disease that typically
affects elderly individuals and is exquisitely sensitive to
anthracyclines. Therefore, future studies on treatment of old
and very old patients with aggressive NHL should be designed
to evaluate, together with less cardiotoxic anthracycline
formulations, cardioprotective strategies and agents as well as
noninvasive monitoring markers and methods to detect early
signs of cardiotoxicity (Albini et al, 2010; Altena et al, 2009).
We documented the feasibility and efﬁcacy of an R-COMP-
14 regimen in poor-risk elderly DLBCL patients with signif-
icant cardiac comorbidity. Many of these high-risk patients,
who eventually achieved complete and durable responses,
would probably have been denied curative treatment based on
the comorbidity burden and age. In the speciﬁc setting of
cardiopathic patients with aggressive NHL, value of liposomal
doxorubicin deserves comparison with the less cardiotoxic
protracted infusions of doxorubicin or newer anthracycline
congeners.
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